Clinical trials: DME
Diabetic Retinopathy
Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients
In this clinical study the Notal Vision Home OCT (NVHO) Monitoring System will be used to evaluate the ability of patients diagnosed with DME to perform sequential self-images of their eyes with the self-operated NVHO device in a…
- Trial name
- NCT05417152
- Where
- Israel
- Volunteers
- 18 people
- Sponsor
- Notal Vision Inc.
Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye.
- Trial name
- NCT05989126
- Testing
- aflibercept 8 mg PFS
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Regeneron Pharmaceuticals
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study Conducted to Evaluate the Conjunctiva and Tenon's Capsule Status of Healthy Subjects and in Participants With Neovascular Age-related Macular Degeneration (nAMD)/Diabetic Macular Edema (DME)
The purpose of this study is to obtain conjunctiva and tenon's capsule thickness measurements in vivo using spectral domain-optical coherence tomography (SD-OCT) in participants with nAMD/DME and age-matched healthy subjects.
- Trial name
- NCT06723288
- Where
- 20 sites in Spain
- Volunteers
- 736 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Diabetic Macular Edema
Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)
Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)
- Trial name
- ELAAVATE (NCT06942520)
- Testing
- RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sierra Eye Associates
Diabetic Macular Edema, Macular Edema Due to Diabetes Mellitus
OCT and OCT-Angiography Biomarkers of Treatment Response to Dexamethasone Implant in Macular Edema Due to Retinal Vascular Diseases - DME and RVO
The purpose of this pilot study is to evaluate different imaging parameters in patients with previously treatment-naive DME and ME due to RVO before and after treatment with dexamethasone implant, in order to find specific…
- Conditions
- Diabetic Macular Edema, Macular Edema Due to Diabetes Mellitus, Retinal Vein Occlusion
- Trial name
- NCT06332690
- Testing
- dexamethasone implant
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Multimedica
Diabetic Macular Edema
Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser
The goal of this pilot study is to investigate the safety and efficacy of micropulse (MP) macular laser in combination with intravitreal aflibercept for the treatment of centre-involved diabetic macular edema.
- Trial name
- DAM (NCT03143192)
- Testing
- Micropulse Laser
- Where
- 2 sites in Canada
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Keyvan Koushan
Diabetic Macular Edema, Diabetic Retinopathy
Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic
The aim of the study is to find out prevalence of diabetic macular edema (DME) in patients with diabetes mellitus in Slovak Republic.The outcome of the project will be epidemiology survey, prevalence of wet form of Diabetic…
- Trial name
- NCT02063321
- Volunteers
- 762 people
- Sponsor
- Emil Martinka
Diabetic Macular Edema
Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of ranibizumab 0.3mg and aflibercept 2.0mg in patients with DME.
- Trial name
- NCT02363621
- Testing
- Ranibizumab 0.3 mg, Aflibercept 2.0 mg
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Arshad Khanani
Diabetic Macular Edema (DME)
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
- Trial name
- NCT06116916
- Testing
- KHK4951, Aflibercept Injection
- Where
- 87 sites in United States, Australia and 2 more
- Volunteers
- 185 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetic Macular Edema
Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)
Diabetic maculopathy is the leading cause of visual impairment in the working-age population in developed countries. Diabetic macular edema can cause impaired visual acuity and so far is treated by laser, vitreous surgery, and…
- Trial name
- MORE (NCT00885794)
- Testing
- Ranibizumab
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT05099094
- Testing
- BD311
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Diabetic Macular Oedema
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.
- Trial name
- NCT06908876
- Testing
- IBI302, Faricimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Diabetic Macular Edema
Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser
This is an investigator-sponsored trial (IST), an open-label pilot study, assessing the safety and biologic activity of bromfenac in subjects with diffuse DME refractory to laser.
- Trial name
- NCT00491166
- Testing
- Bromfenac ophthalmic solution
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Ophthalmic Consultants of Boston
Visual Impairment Due to Diabetic Macular Edema
24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
The purpose of the study is to compare the effect of intravitreal injections of ranibizumab and aflibercept on systemic VEGF levels in DME patients in a detailed time course.
- Trial name
- TIDE DME (NCT02878681)
- Testing
- Ranibizumab, Aflibercept
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Evaluation of IBI302 Injection in nAMD or DME
The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.
- Trial name
- NCT05961007
- Testing
- Intravitreal injection of IBI302(dose 1), Intravitreal injection of IBI302(dose 2), Intravitreal injection of IBI302(dose 3)
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Diabetes Mellitus, Diabetic Retinopathy
A Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)
This study will evaluate the safety and efficacy of AG-014699 in diabetic patients
- Trial name
- NCT00457470
- Testing
- AG-014699
- Sponsor
- Pfizer
Diabetic Retinopathy, Macular Edema
A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST) in…
- Trial name
- NCT03071068
- Testing
- Anti-PlGF recombinant monoclonal antibody, 4mg dose, Anti-PlGF recombinant monoclonal antibody, 8mg dose
- Where
- 13 sites in Czechia, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- ThromboGenics
Diabetic Macular Edema
Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Diabetic Macular Edema (DME).
- Trial name
- NCT02914613
- Testing
- SF0166 Topical Ophthalmic Solution
- Where
- 6 sites in United States
- Volunteers
- 44 people
- Sponsor
- OcuTerra Therapeutics, Inc.
Macular Edema, Diabetic Macular Edema
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Trial name
- NCT02867735
- Testing
- LKA651
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals